188 related articles for article (PubMed ID: 35362393)
1. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.
Tian Y; Lei Y; Fu Y; Sun H; Wang J; Xia F
Curr Cancer Drug Targets; 2022; 22(6):454-462. PubMed ID: 35362393
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib.
Eun JW; Yoon JH; Ahn HR; Kim S; Kim YB; Lim SB; Park W; Kang TW; Baek GO; Yoon MG; Son JA; Weon JH; Kim SS; Cho HJ; Cheong JY
Cancer Commun (Lond); 2023 Apr; 43(4):455-479. PubMed ID: 36919193
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
4. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
[TBL] [Abstract][Full Text] [Related]
6. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
7. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Chen Z; Yuan T; Yan F; Ye S; Xie Q; Zhang B; Lin N; He Q; Yang B; Zhu H
BMC Cancer; 2022 Apr; 22(1):425. PubMed ID: 35440025
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms.
Dahiya M; Dureja H
J Chemother; 2022 Sep; 34(5):286-301. PubMed ID: 34291704
[TBL] [Abstract][Full Text] [Related]
9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
10. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Suzuki H; Iwamoto H; Seki T; Nakamura T; Masuda A; Sakaue T; Tanaka T; Imamura Y; Niizeki T; Nakano M; Shimose S; Shirono T; Noda Y; Kamachi N; Sakai M; Morita K; Nakayama M; Yoshizumi T; Kuromatsu R; Yano H; Cao Y; Koga H; Torimura T
Cancer Commun (Lond); 2023 Apr; 43(4):415-434. PubMed ID: 36825684
[TBL] [Abstract][Full Text] [Related]
12. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
14. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
15. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
16. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
17. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
18. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
de Rosamel L; Blanc JF
Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
[TBL] [Abstract][Full Text] [Related]
19. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW
PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338
[TBL] [Abstract][Full Text] [Related]
20. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
